Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The HPV18 E6 protein is a viral oncoprotein from high-risk human papillomavirus type 18, characterized by two zinc-binding domains and a C-terminal PDZ-binding motif (e.g., R-R-R-E-T-Q-V). It plays a principal role in cellular transformation by binding E6AP to ubiquitinate and degrade host proteins like p53, MAGI-1, SAP97/hDlg, and AIF, thereby disrupting apoptosis, cell cycle control, and tumor suppression. This enables cell immortalization and malignancy, particularly in cervical cancer. Structural studies show E6's peptide forms an extended β-sheet with PDZ grooves, with unique residues like R-5 enhancing specificity. High-risk E6 variants exhibit stronger PDZ interactions than low-risk types
Binds PDZ domains of MAGUK proteins (e.g., MAGI-1, SAP97) via C-terminal peptide motif for ubiquitin-mediated degradation Forms complex with E6AP (E3 ubiquitin ligase) to degrade p53 and AIF Targets class I PDZ domain-containing proteins for proteasomal degradation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HPV18 E6 protein (Human papillomavirus type 18 E6 protein) (E6).